Haleon (Haleon) Asset Impairment Charge : $0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Asset Impairment Charge?

Haleon's Asset Impairment Charge for the three months ended in Mar. 2024 was $0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.

Haleon Asset Impairment Charge Historical Data

The historical data trend for Haleon's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Asset Impairment Charge Chart

Haleon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Haleon Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial									-	-	-	-	-

Haleon Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Haleon Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Haleon's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (Haleon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (NYSE:HLN) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN1:Mexico HLNl:UK HLN:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.